Patient Safety and Medical Devices Sonia Swayze, RN, MA, C and Suzanne Rich, RN, MA, CT.

Slides:



Advertisements
Similar presentations
Postmarket Surveillance of Medical Device Adverse Events Hesha Jani Duggirala, PhD Epidemiology Branch Division of Postmarket Surveillance Office of Surveillance.
Advertisements

Overview of FDA Device Regulations
Safety Guidelines Illness and Injury Prevention Safety Guidelines Illness and Injury Prevention 2.01 Understand safety procedures 1.
Humanitarian Device Exemptions (HDE) 101 Elizabeth Hillebrenner, MSE Biomedical Engineer IDE and HDE Program Staff Center for Devices and Radiological.
Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.
Capturing and Reporting Adverse Events in Clinical Research
Introduction to Regulation
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
Special Topics in IND Regulation
Medical Devices Approval Process
Field Investigators: ADE Detectives. Section One Introduction to the Team and Their Roles.
FDA’s MedWatch Program Outreach to Healthcare Professionals and the Public n Managing the Risks of Medical Product Use.
The FDA Landscape AdvaMed September 2008 Judith K. Meritz
+ Medical Devices Approval Process. + Objectives Define a medical device Be familiar with the classification system for medical devices Understand the.
Mrs. Brandi Robinson Office of New Animal Drug Evaluation Center for Veterinary Medicine Regulating Animal Drugs.
FDA MedWatch and Patient Safety. Dietary Supplement and Nonprescription Drug Consumer Protection Act of 2006  The Act defines a ‘serious adverse event’
Adverse Event Reports on Automatic External Defibrillators from Oscar H Tovar MD and Beverly Gallauresi RN, MPH Food and Drug Administration.
Eureka Pre-Clinical Investigation Animal toxicology Animal pharmacokinetics/ pharmacodynamics Clinical Investigation Phase I Safety and pharmacology Phase.
POSTMARKETING ADVERSE DRUG EXPERIENCE INSPECTIONAL PROGRAM CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO.
Center for Veterinary Medicine (CVM) RECALLS.  21 CFR 7.40 provides guidance on the policy, procedures, and industry responsibilities for recalls. 
Special Issues in FDA-Regulated Studies: The Good, the Bad, and the Ugly C. Karen Jeans, MSN, CCRN, CIP COACH Program Analyst VA Office of Research & Development.
Center for Drug Evaluation and Research August 2005 Electroretinography: The FDA’s Viewpoint Wiley A. Chambers, MD Deputy Director Division of Anti-Infective.
FDA Regulatory review in Minutes: What Product Development Executives Need-to-Know. Specifically, frequent causes of recalls and related areas that investigators.
What Makes a Good Medical Device Adverse Event Report?
Stakeholders In Clinical Research Government and Regulatory Bodies Professor Phil Warner.
The Medical Device Pathway as a Legal Onramp for Futuristic Persons THE FUTURE T HE M EDICAL D EVICE P ATHWAY AS A L EGAL.
Top 10 Medical Device Citations
INTRODUCTION TO RA.
Investigational New Drug Application (IND)
REGULATORY CHALLENGES FOR NANOMATERIALS IN PUBLIC HEALTH Driving Faster Than Our Nano-Headlights AAAS Annual Meeting February 13, 2009 Norris E. Alderson,
3/3/2010Handshake to Success Crescent Healthcare is a premier infusion company founded in 1992 to provide home infusion services to patients with chronic.
From the Lab to Market Unit 3.04 Understanding Biotechnology research & Development.
FDA Focus On Consumer Protection
Regulatory Big Brother of Biotechnology. Role of FDA FDA was designed to promote and protect the public’s health Food and Drug Cosmetic Act first passed.
Bibliography Amoore, J., Ingram, P. (2002, August). Quality improvement report: Learning from adverse incidents involving medical devices. British Medical.
PATRICIA KERBY, MPA HUMAN SUBJECTIONS PROTECTION COMPLIANCE OFFICER OFFICE OF RESEARCH COMPLIANCE What are the FDA’s expectations in 2010?
Food and Drug Administration & Outbreaks
Humanitarian Use Devices September 23, 2011 Theodore Stevens, MS, RAC Office of Cellular, Tissue and Gene Therapies Center for Biologics Evaluation and.
CDRH INITIATIVES FOR AGING IN PLACE NIH Aging in Place Workshop September 10-11, 2014 Presented by Mary Brady, MSN, RN Senior Policy Advisor Center for.
Rules for Supporting Part 803 and Part 806 Decision Making Page 1 Establishing Rules for: Medical Device Reports (803) & Correction and Removal Reports.
CHAPTER 10 CONSUMER PROTECTION
Nanotechnology - USDA - 18 Nov 2002 REGULATORY CONSIDERATIONS FOR NANOTECHNOLOGY IN PUBLIC HEALTH FOOD AND DRUG ADMINISTRATION Norris E. Alderson, Ph.D.
UPCOMING CHANGES TO IN-VITRO DIAGNOSTICS (IVDs) AND LABORATORY DEVELOPED TESTS (LDTs) REGULATIONS Moj Eram, PhD November 5, 2015.
Investigational Devices and Humanitarian Use Devices June 2007.
Title Page Quality Mo Samimi, Ph.D. CMQ/OE Presented at the ASQ Biomedical Division Northern California Discussion Group. May 2011.
BIORESEARCH MONITORING & IN VITRO DIAGNOSTIC DEVICES Presented by Jean Toth-Allen, Ph.D. Biophysicist/Consumer Safety Officer Division of Bioresearch Monitoring.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
FDA Notifications and Medwatch Form Requirements Adverse Event Reporting for OTC Drugs and Dietary Supplements.
Complaint Handling Medical Device Reporting May 19, 2016 Rita Harden, Director Customer Relations & Regulatory Reporting.
Storage, Labeling, Controlled Medications Guidance Training CFR § (b)(2)(3)(d)(e) F431.
Clinical Trials.
KEVIN BEDAL LISA CARLIN MATT CARROLL ERIN NICHOLS Product Safety & Failure Analysis.
RAC Regulatory Affairs Certification

The Working Group on Medical Measurements The 23rd Forum Meeting
How to Put Together an IDE Application
FDA Perspective on Cardiovascular Device Development
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
Reasonable Assurance of Safety and Effectiveness: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division.
American Society for Quality Region 5 Quality Conference
Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
Combination products The paradigm shift
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
Safety Guidelines Illness and Injury Prevention
Visualization Using Open-Source Tools: some FDA perspectives
Patient Involvement in the Development and Safe Use of
Opening an IND: Investigator Perspective
Tobey Clark, Director*, Burlington USA
Safety Guidelines Illness and Injury Prevention
Safety Guidelines Illness and Injury Prevention
Presentation transcript:

Patient Safety and Medical Devices Sonia Swayze, RN, MA, C and Suzanne Rich, RN, MA, CT

Objectives Discuss the impact of FDA’s consumer protections on patient safetyDiscuss the impact of FDA’s consumer protections on patient safety Describe the Medical Device Reporting Regulation as a model for patient safetyDescribe the Medical Device Reporting Regulation as a model for patient safety Identify criteria for FDA’s CDRH medical device adverse event report review and evaluationIdentify criteria for FDA’s CDRH medical device adverse event report review and evaluation Conduct an abbreviated medical device adverse event report review to identify a patient safety problemConduct an abbreviated medical device adverse event report review to identify a patient safety problem Create a model for patient safetyCreate a model for patient safety

FDA, Medical Devices, and Patient Safety FDA, Medical Devices, and Patient Safety Food and Drug Administration (FDA)Food and Drug Administration (FDA) –promotes the safe and effective use of medical devices, drugs, biologics, foods, and cosmetics through consumer protection programs FDA’s consumer protections are in place to:FDA’s consumer protections are in place to: –safely bring new products to market, and –to ensure that safe and effective products remain on the market

FDA at a Glance FDA is divided into 7 Centers, each with its own area of responsibility:FDA is divided into 7 Centers, each with its own area of responsibility: –Center for Medical Devices –Center for Drugs –Center for Biologics –Center for Food Safety and Applied Nutrition –Center for Toxicology and Research –Center for Veterinary Medicine –Center for Regulatory Operations

FDA’s Basic Responsibilities

Risk ManagementRisk Management –First human use (IND or IDE) –Safe Experimental use (product development) –Widespread Use (market approval) –Post-market Adverse Event Experience Evaluation

FDA’s Basic Responsibilities Integrity AssuranceIntegrity Assurance –Enforcement FraudFraud Bad Manufacturing PracticesBad Manufacturing Practices Bad Clinical PracticesBad Clinical Practices

FDA’s Basic Responsibilities Science-Based Regulatory DecisionsScience-Based Regulatory Decisions EvidenceEvidence –Clinical Trial Data –Post-market Adverse Event Experience Data –Standards

FDA’s Center for Devices and Radiological Health (CDRH) Mission CDRH promotes and protects the health of the public by ensuring the safety and effectiveness of medical devices and radiological products Vision Ensuring the health of the public throughout the Total Product Life Cycle

Total Product Life Cycle Early Product Life Cycle –Concept What is the product?What is the product? –Device, Pharmaceutical, Biological? –Combination product? –Prototype What makes the product new?What makes the product new? –Biomaterials –Design –Indication? –What is already known? i.e. does the product leach, oxidize?i.e. does the product leach, oxidize?

Mid-Product Life Cycle Pre-clinical EvaluationPre-clinical Evaluation –Are there critical performance specifications? –Standards – i.e. International Standards Organization. Clinical EvaluationClinical Evaluation –Use with final manufactured product or prototype? –Are there any unforeseen adverse events? Manufacturing EvaluationManufacturing Evaluation –controls – i.e., human factors, design, manufacturing process considerations Manufacturing for marketing and commercial useManufacturing for marketing and commercial use –Pre-approval FDA inspection –Supplier – component integrity –Consignees – user training and education –Promotion and Advertising –Labeled indications for use

Late Product Life Cycle Product MarketingProduct Marketing –Promotion and Advertising –Truthful Labeling Commercial UseCommercial Use –Unforeseen problems –Device Failures –Product re-design Obsolescence Obsolescence –Use and End-of-Life Considerations Customer complaints and complaint investigationCustomer complaints and complaint investigation –Use errors –Failure analysis Adverse event reportingAdverse event reporting

Device: Simply Defined * Item used for diagnosis, treatment or prevention of disease, injury or other condition that is not a drug, biologic or food. * Actual definition of a device can be found in FD&C Act, Section 201(h).

Medical Device Adverse Event Reporting A model for patient safetyA model for patient safety –Identification and reporting of adverse events involving medical devices, patients, and users –Information used to evaluate actual and potential problems with medical devices during use

What is an Adverse Event ? An event whereby a death or serious injury was, or may have been caused by a medical device. An event whereby a medical device was, or may have contributed to a death or serious injury. Includes events resulting from: Includes events resulting from: - device failure- improper / inadequate design - device malfunction- manufacturing (problems) - use error- labeling (problems)

Serious Injury results in permanent impairment / damage to body function / structure requires medical or surgical intervention to preclude permanent impairment / damage to body function / structure requires medical or surgical intervention to preclude permanent impairment / damage to body function / structure. Life-Threatening Injury or Illness

Malfunction The failure of a device to meet its performance specifications or otherwise perform as intended. A malfunction is reportable: when it is likely to cause or contribute to a death or serious injury if it were to recur. (Malfunctions are not required to be reported by User Facilities)

CDRH Reporting Programs Voluntary - MedWatch -Reporting by healthcare professionals and consumers -Report actual or potential product problems Mandatory -User Facilities -Report deaths and serious injuries -Manufacturers -Report deaths, serious injuries, and malfunctions

Mandatory Reporting User Facilities User Facilities required to report deaths and serious injuriesUser Facilities required to report deaths and serious injuries –1990 Safe Medical Device Act (SMDA) 11/28/90 –Effective date for User Facilities 11/28/91 –Effective date of Final Rule to implement MDR 7/31/96 MDR Regulation CFR 803

What is a User Facility? Hospitals Ambulatory Surgical Centers Nursing Homes Outpatient Diagnostic Facilities Outpatient Treatment Facilities

Mandatory Reporting Manufacturers Manufacturers required to report deaths, serious injuries, and malfunctions –Initial Regulation requiring MDR reporting effective 12/13/84 –Reporting requirements revised by SMDA 1990 & 1992 Amendments effective 7/31/96 MDR Regulation CFR 803

What is a Manufacturer? Defined to include: Domestic ManufacturersDomestic Manufacturers Foreign ManufacturersForeign Manufacturers Repackagers / RelabelersRepackagers / Relabelers Component ManufacturersComponent Manufacturers Hospitals ReprocessingHospitals Reprocessing Single-Use Devices

REPORTING TIMEFRAMES Deaths Serious Injury (if manufacturer unknown) manufacturer unknown) FDA User Facility Death and Serious Injury Manufacturer Deaths Serious Injury Malfunction